In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurocrine Biosciences Inc.

www.neurocrine.com

Latest From Neurocrine Biosciences Inc.

Parkinson’s Disease: Novel Science And Collaborations Fuel Progress

Novel therapeutic strategies for Parkinson’s disease have brought a renewed sense of optimism to those researching this neurodegenerative disorder. Numerous treatment avenues are being explored, including small molecules, gene therapy, cell therapy and medical devices to stimulate nerves deep in the brain. Digital also gets a look-in, being useful for analyzing gait and other symptoms, and addressing both mental and physical issues.

BioPharmaceutical Neurology

ObsEva Gives Up On IVF Drug As Phase III Study Fails

Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.

Clinical Trials Companies

Patience Pays Off For Kyowa Kirin As Nourianz Finally Gets US FDA OK

The Japanese firm's original 2007 NDA was rejected in 2008 but it kept faith in the drug, now approved as an adjunct to levodopa/carbidopa. At least one competitor is waiting in the wings.

Approvals Neurology

AbbVie Revs Up The Race To Market In Uterine Fibroids

AbbVie and Neurocrine submitted an NDA to FDA for elagolix for bleeding associated with uterine fibroids, leading in what is expected to be a competitive market.

Gynecology & Urology Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gynecological, Urological
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Neurocrine Biosciences Inc.
  • Senior Management
  • Kevin C Gorman, PhD, CEO
    Kyle Gano, PhD, Chief Bus. Dev. Officer
    Haig Bozigian, PhD, Chief Dev. Officer
    Dimitri Grigoriadis, PhD, Chief Research Officer
    Malcolm Lloyd-Smith , Chief Reg. Officer
    Christopher O'Brien, MD, CMO
  • Contact Info
  • Neurocrine Biosciences Inc.
    Phone: (858) 617-7600
    12780 El Camino Real
    San Diego, CA 92130
    USA
UsernamePublicRestriction

Register